Scholars Central

Conference abstractPublished 3 Sep 2018

Hydromorphone induced neurotoxicity in palliative care

Authors: Olfat Zekry

The University of Sydney, Australia

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Opioids are commonly used for pain control in palliative care settings. Accumulation of active metabolites of opioids can cause a well-recognized toxidrome including sedation, hallucinations, myoclonus, seizures and cognitive dysfunction. Sedation, which is the most commonly seen symptom of toxicity, leads to delirium and obtundation. Opioid toxicity is often associated with the amount ingested and its speed of absorption in the body. This can have life-threatening effects on various body systems. Gaining expertise with the use of hydromorphone for chronic pain management should be the primary goal of those managing pain in the terminally ill patient. There is a wide choice of routes of administration and the adverse effects may be minimized by careful dose adjustment, particularly in patients with renal failure or in the elderly. When alternatives are indicated for more severe pain, methadone or fentanyl may be considered. When a patient is not responding to opioids, review the pain diagnosis with the causes of opioid-insensitive pain in mind, particularly bone and neuropathic pain. Rotation of the one opioid to another should be considered. Co-analgesics or one of the recently developed NMDA receptor antagonists may also be required. We will discuss a case study involving Anne-Marie, a 65 years old female with refractory myeloma, on a regular dialysis program and chronic back pain. She was due to commence radiotherapy to the femoral lesion and was admitted to RPA with escalating pain and severe drowsiness. She complained of pain everywhere, but it was worst in the left femoral and left L2/3 spinal regions with decreased mobility and sudden cramping. Her analgesic medication: Fentanyl patch 175 mcg/hr every 3 days, Fentanyl lozenges 200 mcg Q4h PRN if inadequate relief, Hydromorphone S/C 5 mg Q4h and PRN with rapid escalation by renal team and Gabapentin 200 mg pre-dialysis and 400 mg post-dialysis. Finally, a discussion about opioid induced neurotoxicity and management will be presented.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Palliative Care & Medicine.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Palliative Care & Medicine
  • SubjectAlternative & Palliative Care
  • BylineArticles whose byline prints “Olfat Zekry”